Physician profile
Edwin Gannon
NPI 1205362571
$3,399.71
in general payments reported to CMS, 2019-2025
14 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $800 · 2023: $491 · 2024: $532 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,182.06 | 2022-2025 | |
| Alcon Vision LLC | $924.31 | 2021-2025 | Clareon Panoptix Pro, Rocklatan, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $374.28 | 2022-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $258.35 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $167.61 | 2022-2023 | Tyrvaya |
| Lensar, INC. | $165.61 | 2025 | Lensar Laser System |
| Bausch & Lomb Americas INC. | $107.33 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Thea Pharma INC. | $71.62 | 2025 | Iyuzeh |
| Biotissue Holdings INC. | $41.44 | 2024-2025 | |
| Allergan, INC. | $35.78 | 2022 | |
| Aerie Pharmaceuticals, INC. | $22.81 | 2021 | |
| Glaukos Corporation | $17.89 | 2022 | |
| Harrow Eye, LLC | $16.61 | 2024 | Vevye |
| Sight Sciences, INC. | $14.01 | 2024 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Gannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.